menu
    • menu
    [{"orgOrder":0,"company":"DiogenX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"DiogenX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DiogenX \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"DiogenX \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Series A Financing","leadProduct":"PATAS","moa":"ALMS1","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AdipoPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"4","companyTruncated":"AdipoPharma \/ Newton Biocapital"},{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Funding","leadProduct":"PATAS","moa":"ALMS1","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AdipoPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"4","companyTruncated":"AdipoPharma \/ Newton Biocapital"},{"orgOrder":0,"company":"Alize\u0301 Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Alize\u0301 Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alize\u0301 Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alize\u0301 Pharma \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AdipoPharma

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            AdipoPharma

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PATAS

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Newton Biocapital

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            AdipoPharma Secures Funding for Insulin Resistance Clinical Trials

                            Details : The funding will enable AdipoPharma to accelerate its clinical development of a first-in-class compound, PATAS, that directly targets insulin resistance, the root cause of Type 2 diabetes.

                            Product Name : PATAS

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            November 11, 2024

                            Lead Product(s) : PATAS

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Newton Biocapital

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            DiogenX

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            DiogenX

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            DiogenX Raises €27.5M Series A Financing To Advance its First-in-class Regenerative Treatment For Type 1 Dia...

                            Details : The proceeds will advance company's lead drug, a potential first-in-class, disease-modifying recombinant protein designed to modulate the Wnt/β-catenin signalling pathway to regenerate pancreatic insulin-producing beta cells ,into clinical development i...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AdipoPharma

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            AdipoPharma

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PATAS

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Newton Biocapital

                            Deal Size : Undisclosed

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            French Biotech Company AdipoPharma Secures Series A Funding for Groundbreaking Diabetes Drug

                            Details : AdipoPharma uses a novel approach to treating Type 2 diabetes. AdipoPharma’s drug, PATAS, treats insulin resistance, the root cause of Type 2 diabetes. PATAS has been designed while working on fat cells known as adipocytes.

                            Product Name : PATAS

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            January 23, 2023

                            Lead Product(s) : PATAS

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Newton Biocapital

                            Deal Size : Undisclosed

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alizé Pharma

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            Alizé Pharma

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alize Pharma 3 Announces Rebranding to Amolyt Pharma

                            Details : Amolyt Pharma is developing AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, as well as AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism.

                            Product Name : AZP-3601

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            February 06, 2020

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth